Abstract 658: CBS9106 is a novel low toxic reversible oral CRM1 inhibitor with CRM1 degrading activity
Sakakibara, Keiichi, Saito, Naoya, Sato, Takuji, Suzuki, Atsushi, Hasegawa, Yoko, Friedman, Jonathan M., Suganuma, Masashi, Kufe, Donald W., VanHoff, Daniel D., Iwami, Tadahiko, Kawabe, Takumi
Published in Cancer research (Chicago, Ill.) (15.04.2011)
Published in Cancer research (Chicago, Ill.) (15.04.2011)
Get full text
Journal Article